Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC Ads To Be Studied By FDA With Eye On Efficacy Presentations

Executive Summary

A study proposed by FDA to evaluate how benefit information is conveyed through direct to consumer advertisements could end up showing drug marketers how to describe "high" and "low" efficacy drugs

You may also be interested in...

FDA May Allow "Qualitative" Labels For Data In DTC Ads

Study of "format variations" in the brief summary of print advertisements will test different ways of presenting benefit and risk information.

Opening Product Labeling To Broader CE Data Is Proposed In Senate Bill

Drug product labels could contain an array of comparative effectiveness data beyond well-controlled clinical trials, if Sens. Jack Reed, D-R.I., and Barbara Mikulski, D-Md., get their way

“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study

FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts